These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20596675)

  • 1. Monoclonal antibody (mAb)-induced down-regulation of RON receptor tyrosine kinase diminishes tumorigenic activities of colon cancer cells.
    Li Z; Yao H; Guin S; Padhye SS; Zhou YQ; Wang MH
    Int J Oncol; 2010 Aug; 37(2):473-82. PubMed ID: 20596675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RON receptor tyrosine kinase as a target for delivery of chemodrugs by antibody directed pathway for cancer cell cytotoxicity.
    Guin S; Yao HP; Wang MH
    Mol Pharm; 2010 Apr; 7(2):386-97. PubMed ID: 20039696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase.
    Guin S; Ma Q; Padhye S; Zhou YQ; Yao HP; Wang MH
    Cancer Chemother Pharmacol; 2011 May; 67(5):1073-83. PubMed ID: 20658288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The monoclonal antibody Zt/f2 targeting RON receptor tyrosine kinase as potential therapeutics against tumor growth-mediated by colon cancer cells.
    Yao HP; Zhou YQ; Ma Q; Guin S; Padhye SS; Zhang RW; Wang MH
    Mol Cancer; 2011 Jul; 10():82. PubMed ID: 21749705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agonistic monoclonal antibodies potentiate tumorigenic and invasive activities of splicing variant of the RON receptor tyrosine kinase.
    Yao HP; Luo YL; Feng L; Cheng LF; Lu Y; Li W; Wang MH
    Cancer Biol Ther; 2006 Sep; 5(9):1179-86. PubMed ID: 16880737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological evaluation of antibody-maytansinoid conjugates as a strategy of RON targeted drug delivery for treatment of non-small cell lung cancer.
    Feng L; Yao HP; Zhou YQ; Zhou J; Zhang R; Wang MH
    J Exp Clin Cancer Res; 2016 Apr; 35():70. PubMed ID: 27102688
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
    Yao HP; Feng L; Weng TH; Hu CY; Suthe SR; Mostofa AGM; Chen LH; Wu ZG; Wang WL; Wang MH
    Mol Pharm; 2018 Aug; 15(8):3260-3271. PubMed ID: 29944378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
    Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
    J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of anti-RON antibody Zt/g4-drug maytansinoid conjugation (Anti-RON ADC) as a novel therapeutics for targeted colorectal cancer therapy.
    Feng L; Yao HP; Wang W; Zhou YQ; Zhou J; Zhang R; Wang MH
    Clin Cancer Res; 2014 Dec; 20(23):6045-58. PubMed ID: 25294907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE.
    Suthe SR; Yao HP; Weng TH; Hu CY; Feng L; Wu ZG; Wang MH
    Mol Cancer Ther; 2018 Dec; 17(12):2654-2664. PubMed ID: 30275241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RON Receptor Tyrosine Kinase in Tumorigenic Stemness as a Therapeutic Target of Antibody-drug Conjugates for Eradication of Triple-negative Breast Cancer Stem Cells.
    Suthe SR; Yao HP; Weng TH; Wang MH
    Curr Cancer Drug Targets; 2023; 23(2):103-117. PubMed ID: 36028965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibody Zt/g4 targeting RON receptor tyrosine kinase enhances chemosensitivity of bladder cancer cells to Epirubicin by promoting G1/S arrest and apoptosis.
    Chen JF; Yu BX; Yu R; Ma L; Lv XY; Cheng Y; Ma Q
    Oncol Rep; 2017 Feb; 37(2):721-728. PubMed ID: 28075465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic evaluation of monoclonal antibody-maytansinoid conjugate as a model of RON-targeted drug delivery for pancreatic cancer treatment.
    Yao HP; Feng L; Zhou JW; Zhang RW; Wang MH
    Am J Cancer Res; 2016; 6(5):937-56. PubMed ID: 27293990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained expression of the RON receptor tyrosine kinase by pancreatic cancer stem cells as a potential targeting moiety for antibody-directed chemotherapeutics.
    Padhye SS; Guin S; Yao HP; Zhou YQ; Zhang R; Wang MH
    Mol Pharm; 2011 Dec; 8(6):2310-9. PubMed ID: 22014215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA-mediated gene silencing of the RON receptor tyrosine kinase alters oncogenic phenotypes of human colorectal carcinoma cells.
    Xu XM; Wang D; Shen Q; Chen YQ; Wang MH
    Oncogene; 2004 Nov; 23(52):8464-74. PubMed ID: 15378025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The RON receptor tyrosine kinase is a potential therapeutic target in Burkitt lymphoma.
    Tong X; Zhang X; Fan J; Tong Y; Li S; Jin J; Yao H
    Cancer Biol Ther; 2013 Apr; 14(4):370-7. PubMed ID: 23360784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential therapeutics specific to c-MET/RON receptor tyrosine kinases for molecular targeting in cancer therapy.
    Wang MH; Padhye SS; Guin S; Ma Q; Zhou YQ
    Acta Pharmacol Sin; 2010 Sep; 31(9):1181-8. PubMed ID: 20694025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.
    O'Toole JM; Rabenau KE; Burns K; Lu D; Mangalampalli V; Balderes P; Covino N; Bassi R; Prewett M; Gottfredsen KJ; Thobe MN; Cheng Y; Li Y; Hicklin DJ; Zhu Z; Waltz SE; Hayman MJ; Ludwig DL; Pereira DS
    Cancer Res; 2006 Sep; 66(18):9162-70. PubMed ID: 16982759
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking tumorigenic activities of colorectal cancer cells by a splicing RON receptor variant defective in the tyrosine kinase domain.
    Wang MH; Lao WF; Wang D; Luo YL; Yao HP
    Cancer Biol Ther; 2007 Jul; 6(7):1121-9. PubMed ID: 17611409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study of RON mediated invasion of Raji cell line and drug-target effects].
    Zhan BC; Dong YH; Fan J; Yao HP; Jin J; Tong XM
    Zhonghua Xue Ye Xue Za Zhi; 2013 Nov; 34(11):926-30. PubMed ID: 24294846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.